Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06849414

The Relationship Between Homocysteine and Manifestation of Parkinson's Disease Patients

The Relationship Between Blood Homocysteine Level and Motor and Cognitive Manifestation of Parkinson's Disease Patients

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
44 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

* The aim of the current study is to investigate the association between blood homocysteine level and motor as well as cognitive manifestation of PD patients in Assiut governorate. * Secondary goal is to investigate the association between levels of serum ferritin, iron as well as acute phase proteins (fibrinogen, D-dimer, CRP) and manifestation of PD.

Detailed description

Parkinson's disease (PD) is a common progressive neurodegenerative disease which severely affect the quality of life.It was first described by James Parkinson in 1817 as the most prevalent movement disorder and the second most common neurodegenerative disease after Alzheimer's disease (AD). The etiology of PD remains largely elusive, and the majority of PD cases are of unknown cause. Homocysteine is included in the pathogenesis of neurodegenerative diseases including PD. Also, patients with hyperhomocysteinemia are more prone to depression and cognitive impairment .Homocysteine is implicated in neurodegenerative diseases via inflammatory response and oxidative stress. Several studies indicated that iron metabolism is dysregulated in PD. An important fact is the iron loading in dopaminergic neurons of the substantia nigra pars compacta (SNc), which are the cells primarily affected in PD leading to increased neuronal iron and iron-mediated reactive oxygen species (ROS) generation . Increased Hcy level can facilitate pathological aggregation of proteins involved in neurodegenerative disorders and be toxic to dopaminergic neurons as α synuclein. Homocysteine can modify α synuclein to form more toxic fibrils that are resistant to digestion by proteinases and exhibit propagation activity. D-dimer serve as risk factor for development of deep venous thrombosis (DVT) in patients with early PD. Fibrinogen play a role in exacerbating the neuropathological features of neurodegenerative diseases such as PD through regulating pathophysiological mechanisms and signaling pathways while depletion of fibrinogen helps to ameliorate cognitive function impairment in those patients.

Conditions

Timeline

Start date
2025-06-01
Primary completion
2026-06-01
Completion
2026-07-01
First posted
2025-02-27
Last updated
2025-02-27

Source: ClinicalTrials.gov record NCT06849414. Inclusion in this directory is not an endorsement.